NASDAQ: ATLNAtlantic International Corp Stock
$3.00-0.10 (-3.23%)
Updated May 8, 2025
ATLN Price
$3.00
Fair Value Price
N/A
Market Cap
$187.25M
52 Week Low
$2.00
52 Week High
$8.98
P/E
-0.82x
P/B
-15.58x
P/S
0.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$442.61M
Earnings
-$135.48M
Gross Margin
10.7%
Operating Margin
-26.68%
Profit Margin
-30.6%
Debt to Equity
-11.22
Operating Cash Flow
-$6M
Beta
0.72
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ATLN Overview
SeqLL Incorporated is a life sciences instrumentation and research services company focused on the manufacture of genetic analysis technologies. It offers a True Single Molecule Sequencing (tSMS) platform (a single molecule solution for DNA and RNA sequencing). The company has positioned itself to address gaps left by standard sequencing technologies in RNA transcriptome analysis and specialty DNA analysis. It serves academic and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations. The company was founded in 2013 and is headquartered in Billerica, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATLN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Staffing & Employment Service
Industry Rating
B
ATLN
Ranked#11 of 19
Ranked#11 of 19
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.86 | A | |
| $66.59 | B | |
| $16.45 | B |
Be the first to know about important ATLN news, forecast changes, insider trades & much more!
ATLN News
Overview
Due Diligence Score
–
Industry Average (33)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATLN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATLN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ATLN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ATLN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ATLN due diligence checks available for Premium users.
Valuation
ATLN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.82x
Industry
30.31x
Market
24.22x
ATLN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-15.58x
Industry
10.08x
ATLN's financial health
Profit margin
Revenue
$129.5M
Net Income
-$68.7M
Profit Margin
-53%
ATLN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ATLN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$122.8M
Liabilities
$134.8M
Debt to equity
-11.22
ATLN's short-term liabilities ($97.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATLN's short-term assets ($88.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATLN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$426.3k
Investing
-$23.1k
Financing
-$269.7k
ATLN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATLN vs Staffing & Employment Service Stocks
Atlantic International Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.